Stockscreener 앱 받기
46.29
2.05%
-0.97
시간 외 거래:
46.79
0.50
+1.08%
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - Nasdaq
The Best Biotech Stocks to Buy - Morningstar
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short Interest - MarketBeat
CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024 - Insider Monkey
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More - Yahoo Finance
Gene Editing Tools Market Size, Growth Opportunities, - openPR
First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - The Manila Times
Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million - Investing.com India
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million By Investing.com - Investing.com UK
Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst A Flat Market - Barchart
CRISPR Therapeutics' SWOT analysis: gene editing pioneer faces casgevy launch challenges - Investing.com India
Crispr Therapeutics Q3 EarningsNo Casgevy Revenue, But Plenty Of Optimism (NASDAQ:CRSP) - Seeking Alpha
(CRSP) Investment Analysis - Stock Traders Daily
What is Chardan Capital's Estimate for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by ARK Investment Management LLC - MarketBeat
CRSP FY2024 EPS Reduced by Brookline Capital Management - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates - MSN
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results - Simply Wall St
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio - Morningstar
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN
CRISPR Therapeutics Sell rating reiterated on recent performance - Investing.com
Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform By Investing.com - Investing.com Canada
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com
Crispr Therapeutics earnings beat by $0.41, revenue fell short of estimates - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Time to Sell? - MarketBeat
CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan
CRISPR Q3: CASGEVY Expands Global Reach, $1.9B Cash Position as Losses Narrow | CRSP Stock News - StockTitan
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average - Zacks Investment Research
0.93%
3.55%
자본화:
|
볼륨(24시간):